Carol Paton

Carol Paton

Auto-generated profile, based on publicly available information

Carol Paton

Prescribing Observatory for Mental Health, Royal College of Psychiatrists, London, UK

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
TBThomas Re Barnes
Thomas Re Barnes
RDRichard Drake
Richard Drake
CPCarol Paton
Carol Paton
SCStephen J Cooper
Stephen J Cooper
BDBill Deakin
Bill Deakin
AYAlison R Yung
Alison R Yung
These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

22 April 2015 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
CPCarol Paton
Carol Paton
MCMichael Angus Crawford
Michael Angus Crawford
SBSumera F. Bhatti
Sumera F. Bhatti
MPMaxine X. Patel
Maxine X. Patel
TBThomas R. E. Barnes
Thomas R. E. Barnes
Guideline recommendations for the pharmacologic treatment of personality disorder lack consensus, particularly for emotionally unstable personality disorder (EUPD), and there is limited information on current prescribing practice in the United Kingdom. To characterize the nature and quality of current prescribing practice for personality disorder across the United Kingdom, as part of a quality improvement program. A cross-sectional survey of self-selected psychiatric services providing care for adults with personality disorder (ICD-10 criteria) was conducted. Data were collected during May 2012. Of 2,600 patients with a diagnosis of personality disorder, more than two-thirds (68%) had a diagnosis of EUPD. Almost all (92%) patients in the EUPD subgroup were prescribed psychotropic medication, most commonly an antidepressant or antipsychotic, principally for symptoms and behaviors that characterize EUPD, particularly affective dysregulation. Prescribing patterns were similar between those who had a diagnosed comorbid mental illness and those who had EUPD alone, but the latter group was less likely to have had their medication reviewed over the previous year, particularly with respect to tolerability (53% vs 43%). The use of psychotropic medication in EUPD in the United Kingdom is largely outside the licensed indications. Whether the treatment target is identified as intrinsic symptoms of EUPD or comorbid mental illness may depend on the diagnostic threshold of individual clinicians. Compared with prescribing for EUPD where there is judged to be a comorbid mental illness, the use of off-label medication for EUPD alone is less systematically reviewed and monitored, so opportunities for learning may be lost. Treatment may be continued long term by default.

1 June 2008 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
CPCarol Paton
Carol Paton
TBThomas R. E. Barnes
Thomas R. E. Barnes
MCMary-Rose Cavanagh
Mary-Rose Cavanagh
DTDavid Taylor
David Taylor
PLPaul Lelliott
Paul Lelliott
Background: Clinical guidelines recommend the routine use of a single antipsychotic drug in a standard dose, but prescriptions for high-dose and combined antipsychotics are common in clinical practice.Aims: To evaluate the effectiveness of a quality improvement programme in reducing the prevalence of high-dose and combined antipsychotic prescribing in acute adult in-patient wards in the UK.Method: Baseline audit was followed by feedback of benchmarked data and delivery of a range of bespoke change interventions, and then by a further audit 1 year later.Results: Thirty-two services participated, submitting data for 3942 patients at baseline and 3271 patients at the 1-year audit. There was little change in the prevalence of high-dose (baseline 36%; re-audit 34%) or combined antipsychotic prescribing (baseline 43%; re-audit 39%). As required (‘p.r.n.’) prescriptions were the principal cause of both high-dose and combined antipsychotic prescribing on both occasions.Conclusions: The quality improvement programme did not have a demonstrable impact on prescribing practice in the majority of services. Future efforts to align practice with clinical guidelines need to specifically target the culture and practice of p.r.n. prescribing.

1 November 2009 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
TBThomas R. E. Barnes
Thomas R. E. Barnes
ASAmber Shingleton-Smith
Amber Shingleton-Smith
CPCarol Paton
Carol Paton
Background Data from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age. Aims To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK. Method The study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health. Results Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity. Conclusions Antipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.

6 September 2004 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
CPC. Paton
C. Paton
RER. Esop
R. Esop
CYC. Young
C. Young
DTD. Taylor
D. Taylor

1 April 2007 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
CPCarol Paton
Carol Paton
CWCraig Whittington
Craig Whittington
TBThomas R. Barnes
Thomas R. Barnes
To conduct a meta-analysis of randomized placebo-controlled trials (RCTs) of clozapine augmentation with another antipsychotic drug in patient with schizophrenia who partially respond to clozapine and compare the results with the findings of relevant open studies. A systematic literature search was conducted to identify eligible RCTs. All baseline, posttreatment, and change scores in these trials were included in the meta-analysis. For change in Brief Psychiatric Rating Scale/Positive and Negative Syndrome Scale total scores, the effect size was calculated, and for the proportion of patients with a reduction in Brief Psychiatric Rating Scale/Positive and Negative Syndrome Scale scores of 20% or more, the relative risk was calculated. There was a total of 166 participants in the 4 eligible RCTs. Pooling effect sizes across these studies revealed clinically important heterogeneity (I = 63.5%). Analyzing by duration accounted for the heterogeneity (I = 0%), whereas analyzing by drug did not (I = 57.5%). The 2 RCTs lasting 10 weeks or more gave an odds ratio of response to treatment of 4.41 (95% confidence interval, 1.38 to 14.07). In 8 open studies identified, the same pattern of response was seen. The main treatment-emergent side effects reported were extrapyramidal side effects and raised serum prolactin. Augmentation of clozapine with another antipsychotic drug in patients with schizophrenic illness that has partially responded to clozapine is worthy of an individual clinical trial. This trial may need to be longer than the 4 to 6 weeks usually recommended for acute antipsychotic monotherapy.